-
Myeloablation followed by hematopoietic stem cell transplantation leads to long-term normalization of systemic sclerosis molecular signatures Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-03-18 Nancy Wareing, Xuan Wang, Lynette Keyes-Elstein, Ellen A. Goldmuntz, Marka A. Lyons, Peter McSweeney, Daniel E. Furst, Richard A. Nash, Leslie J. Crofford, Beverly Welch, Ashley Pinckney, Maureen D. Mayes, Keith M. Sullivan, Shervin Assassi
In the randomized Scleroderma: Cyclophosphamide Or Transplantation (SCOT trial), myeloablation, followed by hematopoietic stem cell transplantation (HSCT), led to normalization of systemic sclerosis (SSc) peripheral blood gene cell (PBC) expression signature at the 26-month visit. Herein, we examined long-term molecular changes ensuing 54 months after randomization for individuals receiving an HSCT
-
Limitations of the updated EULAR recommendations for osteoarthritis Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-03-18 Marius Henriksen
-
The risk of relapse of ANCA-associated vasculitis in a randomized controlled trial of plasma exchange and glucocorticoids Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-03-14 Mats L Junek, Peter A Merkel, Eswari Vilayur, Ron Wald, Nader Khalidi, David Jayne, Michael Walsh
Relapses of ANCA-associated vasculitis are important events that can cause organ dysfunction and reduce quality of life. Understanding the effects of the initial treatments for ANCA-associated vasculitis on the subsequent risk of relapse may help guide monitoring and treatment.
-
Evidence-Based Guideline for the management of osteoporosis in men Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-03-14 Nicholas R. Fuggle, Charlotte Beaudart, Olivier Bruyère, Bo Abrahamsen, Nasser Al-Daghri, Nansa Burlet, Manju Chandran, Mario M. Rosa, Bernard Cortet, Céline Demonceau, Willard Dere, Philippe Halbout, Mickaël Hiligsmann, John A. Kanis, Jean-Marc Kaufman, Andreas Kurth, Olivier Lamy, Andrea Laslop, Stefania Maggi, Radmila Matijevic, Eugene McCloskey, Ali Mobasheri, Maria C. Prieto Yerro, Régis P. Radermecker
-
The prevalence of sarcopenia in spondyloarthritis patients: a meta-analysis Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-03-16 Jiawen Hu, Yiwen Wang, Xiaojian Ji, Yinan Zhang, Kunpeng Li, Feng Huang
Spondyloarthritis (SpA) is a chronic inflammatory disorder that affects sacroiliac joints and spine, resulting in substantial disability. Sarcopenia, characterized by the loss of muscle mass and function, is a prevalent comorbidity in various chronic diseases. However, the exact prevalence of sarcopenia in SpA patients remains uncertain. The objective of this study is to conduct a systematic review
-
TfR1 mediated iron metabolism dysfunction as a potential therapeutic target for osteoarthritis Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-03-16 Wenchao Wang, Zhenkai Ma, Xuemin Feng, Jiabin Ren, Shengyao Sun, Yuandong Shao, Weimin Zhang, Xiaoxia Yang, Jiaming Zhang, Xingzhi Jing
Transferrin receptor-1 (TfR1) plays important roles in controlling cellular iron levels, but its role in OA pathology is unknown. Herein we aim to investigate the role of TfR1 in OA progression and its underlying mechanisms. TfR1 expression in cartilage during OA development were examined both in vivo and in vitro. Then IL-1β was used to induce chondrocytes degeneration in vitro and TfR1 siRNA was
-
Sensitive B-cell receptor repertoire analysis shows repopulation correlates with clinical response to rituximab in rheumatoid arthritis Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-03-16 Sabrina Pollastro, Anne Musters, Giulia Balzaretti, Ilse Niewold, Barbera van Schaik, Signe Hässler, Catharina M. Verhoef, Marc Pallardy, Antoine van Kampen, Xavier Mariette, Niek de Vries
Although B-cell depleting therapy in rheumatoid arthritis (RA) is clearly effective, response is variable and does not correlate with B cell depletion itself. The B-cell receptor (BCR) repertoire was prospectively analyzed in peripheral blood samples of twenty-eight RA patients undergoing rituximab therapy. Timepoints of achieved BCR-depletion and -repopulation were defined based on the percentage
-
The clinical benefits of sodium–glucose cotransporter type 2 inhibitors in people with gout Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-03-12 Chio Yokose, Natalie McCormick, Abhishek Abhishek, Nicola Dalbeth, Tristan Pascart, Frédéric Lioté, Angelo Gaffo, John FitzGerald, Robert Terkeltaub, Meghan E. Sise, James L. Januzzi, Deborah J. Wexler, Hyon K. Choi
-
16s RNA-based metagenomics reveal previously unreported gut microbiota associated with reactive arthritis and undifferentiated peripheral spondyloarthritis Rheumatology (IF 5.5) Pub Date : 2024-03-15 Sakir Ahmed, Soumendu Mahapatra, Rasmita Mishra, Krushna Chandra Murmu, Prasanta Padhan, Punit Prasad, Ramnath Misra
Objectives Reactive arthritis (ReA) provides a unique opportunity to comprehend how a mucosal infection leads to inflammatory arthritis at a distant site without the apparent invasion of the pathogen. Unfortunately, conventional stool cultures after ReA provide limited information, and there is a dearth of metagenomic studies in ReA. The objective of this study was to identify gut microbiota associated
-
Long-term follow-up of 109 children with juvenile idiopathic oligoarthritis after first intra-articular corticosteroid injection Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-03-14 Mojca Zajc Avramovič, Nataša Toplak, Gašper Markelj, Nina Emeršič, Tadej Avčin
To evaluate long-term outcomes and prognostic factors in patients with juvenile idiopathic arthritis (JIA), presenting as oligoarthritis, who received IAC as the first treatment for their disease. We conducted retrospective study at the University Children’s Hospital Ljubljana, Slovenia, from January 2015 to May 2023 in children with JIA, clinically presenting as oligoarthritis receiving intra-articular
-
Concomitant Sjögren’s disease as a biomarker for treatment effectiveness in rheumatoid arthritis - results from the Swiss clinical quality management cohort Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-03-14 Lisa Christ, Seraphina Kissling, Axel Finckh, Benjamin A. Fisher, Sabine Adler, Britta Maurer, Burkhard Möller, Florian Kollert
To investigate the clinical phenotype and treatment response in patients with rheumatoid arthritis (RA) with and without concomitant Sjögren’s disease (SjD). In this observational cohort study, patients with RA from the Swiss Clinical Quality Management in Rheumatic Diseases registry were categorised according to the presence or absence of SjD. To assess treatment effectiveness, drug retention of tumor
-
Risk of Venous Thromboembolism with Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐enriched Rheumatoid Arthritis Patients Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-03-14 Christina Charles‐Schoeman, Roy Fleischmann, Eduardo Mysler, Maria Greenwald, Steven R. Ytterberg, Gary G. Koch, Deepak L. Bhatt, Cunshan Wang, Ted R. Mikuls, All‐shine Chen, Carol A. Connell, John C. Woolcott, Sujatha Menon, Yan Chen, Kristen Lee, Zoltán Szekanecz
ObjectiveThe ORAL Surveillance trial found a dose‐dependent increase in venous thromboembolism (VTE) and pulmonary embolism (PE) events with tofacitinib versus tumor necrosis factor inhibitors (TNFi). We aimed to assess VTE incidence over time and explore risk factors of VTE, including disease activity, in ORAL Surveillance.MethodsPatients with rheumatoid arthritis (RA) aged ≥50 years with ≥1 additional
-
Thorough assessment of the effectiveness of belimumab in a large Spanish multicenter cohort of systemic lupus erythematosus patients Rheumatology (IF 5.5) Pub Date : 2024-03-14 Irene Altabás-González, José María Pego-Reigosa, Coral Mouriño, Norman Jiménez, Andrea Hernández-Martín, Ivette Casafont-Solé, Judit Font Urguelles, José Andrés Román-Ivorra, Marta de la Rubia Navarro, María Galindo-Izquierdo, Tarek Carlos Salman-Monte, Javier Narváez, Paola Vidal-Montal, María Jesús García-Villanueva, Sandra Garrote-Corral, María Ángeles Blázquez-Cañamero, Carlos Marras, María Piqueras-García
Objectives To provide an overview on the current use of belimumab (BLM) in SLE patients in clinical practice and to examine its efficacy in terms of standardized outcomes, drug survival, as well as patient and safety profiles. Methods A longitudinal retrospective multicentre cohort including SLE patients treated with BLM at 18 Spanish centers. Data was collected upon initiation of BLM, at 6 and 12
-
LAMP3 induces ectopic TLR7 expression in salivary gland epithelial cells and amplifies type I IFN production in Sjögren's disease Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-03-13 Hiroyuki Nakamura, Tsutomu Tanaka, Changyu Zheng, Sandra A. Afione, Tatsuya Atsumi, Masayuki Noguchi, Fabiola Reis Oliveira, Ana Carolina F. Motta, Fernando Chahud, Eduardo M. Rocha, Blake M. Warner, John A. Chiorini
-
Enhancing current guidance for psoriatic arthritis and its comorbidities: recommendations from an expert consensus panel Rheumatology (IF 5.5) Pub Date : 2024-03-13 Laura C Coates, Marwan Bukhari, Antoni Chan, Ernest Choy, James Galloway, Nicola Gullick, Alison Kent, Laura Savage, Stefan Siebert, William Tillett, Natasha Wood, Philip G Conaghan
Objectives Existing guidelines for psoriatic arthritis (PsA) cover many aspects of management. Some gaps remain relating to routine practice application. An expert group aimed to enhance current guidance and develop recommendations for clinical practice that are complementary to existing guidelines. Methods A steering committee comprising experienced, research-active clinicians in rheumatology, dermatology
-
A nosology of immune diseases from deep immunophenotyping Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-03-11 Michael F. McDermott
-
Antiphospholipid antibodies as potential predictors of disease severity and poor prognosis in systemic lupus erythematosus-associated thrombocytopenia: results from a real-world CSTAR cohort study Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-03-12 Jun Li, Liying Peng, Lijun Wu, Yufang Ding, Xinwang Duan, Jian Xu, Wei Wei, Zhen Chen, Cheng Zhao, Min Yang, Nan Jiang, Shangzhu Zhang, Qian Wang, Xinping Tian, Mengtao Li, Xiaofeng Zeng, Yan Zhao, Jiuliang Zhao
To investigate the role of antiphospholipid antibodies (aPLs) in the disease severity and prognosis of SLE-related thrombocytopenia (SLE-TP). This multicenter prospective study was conducted based on data from the CSTAR registry. TP was defined as a platelet count<100 × 109/L. Demographic characteristics, platelet count, clinical manifestations, disease activity, and autoantibody profiles were collected
-
Can complement activation be the missing link in antiphospholipid syndrome? Rheumatology (IF 5.5) Pub Date : 2024-03-12 Veronica Venturelli, Beatrice Maranini, Ibrahim Tohidi-Esfahani, David A Isenberg, Hannah Cohen, Maria Efthymiou
APS is an autoimmune disorder with life-threatening complications that, despite therapeutic advantages, remains associated with thrombotic recurrences and treatment failure. The role of complement activation in APS pathogenesis is increasingly recognised, specifically in obstetric APS. However, its exact role in thrombotic APS and on the severity of the disease is not yet fully elucidated. Further
-
Flare prediction after tapering the dose of tumour necrosis factor inhibitors in patients with axial spondyloarthritis: A nationwide cohort study Rheumatology (IF 5.5) Pub Date : 2024-03-12 Jina Yeo, Ju Yeon Kim, Jin Kyun Park, Kichul Shin, Eun Young Lee, Tae-Hwan Kim, Jun Won Park
Objectives To develop a model for predicting flares after tapering the dose of tumour necrosis factor inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA). Methods Data were obtained from the Korean College of Rheumatology Biologics and Targeted Therapy Registry. In total, 526 patients who received the standard-dose TNFi for at least 1 year and tapered their dose were included in the
-
Hydroxychloroquine in lupus or rheumatoid arthritis pregnancy and risk of major congenital malformations: a population-based cohort study Rheumatology (IF 5.5) Pub Date : 2024-03-12 Ngoc V Nguyen, Elisabet Svenungsson, Annica Dominicus, Maria Altman, Karin Hellgren, Julia F Simard, Elizabeth V Arkema
Objectives To assess the infant risk of major congenital malformations (MCM) associated with first-trimester exposure to hydroxychloroquine (HCQ) among mothers with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA). Methods This population-based cohort study utilised Swedish nationwide registers and included all singleton births (2006–2021) among individuals with prevalent SLE or RA in
-
Patient and health professional views on risk-stratified monitoring of immune-suppressing treatment in adults with inflammatory diseases Rheumatology (IF 5.5) Pub Date : 2024-03-12 Amy Fuller, Jennie Hancox, Hywel C Williams, Tim Card, Maarten W Taal, Guruprasad P Aithal, Christopher P Fox, Christian D Mallen, James R Maxwell, Sarah Bingham, Kavita Vedhara, Abhishek Abhishek
Objective To explore the acceptability of an individualised risk-stratified approach to monitoring for target-organ toxicity in adult patients with immune-mediated inflammatory diseases established on immune-suppressing treatment(s). Methods Adults (≥18 years) taking immune-suppressing treatment(s) for at-least six months, and healthcare professionals (HCPs) with experience of either prescribing and/or
-
Machine learning-driven immunophenotypic stratification of mixed connective tissue disease corroborating the clinical heterogeneity Rheumatology (IF 5.5) Pub Date : 2024-03-12 Shinji Izuka, Toshihiko Komai, Takahiro Itamiya, Mineto Ota, Yasuo Nagafuchi, Hirofumi Shoda, Kosuke Matsuki, Kazuhiko Yamamoto, Tomohisa Okamura, Keishi Fujio
Objectives To stratify patients with mixed connective tissue disease (MCTD) based on their immunophenotype. Methods We analyzed the immunophenotype and transcriptome of 24 immune cell subsets from patients with MCTD, systemic lupus erythematosus (SLE), idiopathic inflammatory myopathy (IIM), and systemic sclerosis (SSc) from our functional genome database, ImmuNexUT (https://www.immunexut.org/). MCTD
-
Assessing the sensitivity and specificity of myositis-specific and associated autoantibodies: a sub-study from the MyoCite cohort Rheumatology (IF 5.5) Pub Date : 2024-03-12 Aravinthan Loganathan, Latika Gupta, Alex Rudge, Hui Lu, Elizabeth Bowler, Fionnuala McMorrow, R Naveen, Anamika K Anuja, Vikas Agarwal, Neil McHugh, Sarah Tansley
Objectives Myositis-specific and associated autoantibodies are important biomarkers in routine clinical use. We assessed local testing performance for myositis autoantibodies by comparing line immunoassay (LIA) to protein radio-immunoprecipitation and identifying clinical characteristics associated with each myositis autoantibody in the MyoCite cohort. Methods Serum samples from patients within the
-
Uptake and safety of pneumococcal vaccination in adults with immune mediated inflammatory diseases: a UK wide observational study Rheumatology (IF 5.5) Pub Date : 2024-03-12 Georgina Nakafero, Matthew J Grainge, Tim Card, Christian D Mallen, Jonathan S Nguyen Van-Tam, Abhishek Abhishek
Objective The uptake and safety of pneumococcal vaccination in people with immune mediated inflammatory diseases (IMIDs) is poorly understood. We investigated the UK wide pneumococcal vaccine uptake in adults with IMIDs and explored the association between vaccination and IMID flare. Methods Adults with IMIDs diagnosed on or before 01/09/2018, prescribed steroid-sparing drugs within the last 12 months
-
Predictors and prognosis of pulmonary hypertension complicating interstitial lung disease in systemic sclerosis Rheumatology (IF 5.5) Pub Date : 2024-03-12 Kathleen Morrisroe, Dylan Hansen, Wendy Stevens, Laura Ross, Joanne Sahhar, Gene-Siew Ngian, Catherine Hill, Lauren Host, Jennifer Walker, Susanna Proudman, Mandana Nikpour
Objective To identify those with concurrent pulmonary hypertension (PH) and interstitial lung disease (ILD) in systemic sclerosis (SSc) and determine their disease severity, therapeutic approach, and survival. Methods Consecutive SSc patients enrolled in the Australian Scleroderma Cohort Study (ASCS) who were diagnosed on right heart catherisation with pulmonary hypertension were included. Logistic
-
All fibroblasts are equal, but some are more equal than others Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-03-11 Chrissy Bolton, Adam P. Croft
-
TYK2: an emerging therapeutic target in rheumatic disease Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-03-11 Eric Morand, Joseph F. Merola, Yoshiya Tanaka, Dafna Gladman, Roy Fleischmann
-
Streamlined, single-step non-viral CRISPR-Cas9 knockout strategy enhances gene editing efficiency in primary human chondrocyte populations Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-03-11 Simone Ponta, Angela Bonato, Philipp Neidenbach, Valentino F. Bruhin, Alexis Laurent, Lee Ann Applegate, Marcy Zenobi-Wong, Goncalo Barreto
CRISPR-Cas9-based genome engineering represents a powerful therapeutic tool for cartilage tissue engineering and for understanding molecular pathways driving cartilage diseases. However, primary chondrocytes are difficult to transfect and rapidly dedifferentiate during monolayer (2D) cell culture, making the lengthy expansion of a single-cell-derived edited clonal population not feasible. For this
-
Transcriptomic profiling of osteoarthritis synovial macrophages reveals a tolerized phenotype compounded by a weak corticosteroid response Rheumatology (IF 5.5) Pub Date : 2024-03-11 Cheng Wang, Ruben De Francesco, Lieke A Lamers, Sybren Rinzema, Siebren Frölich, Peter L E M van Lent, Colin Logie, Martijn H J van den Bosch
Objectives It is well-known that long-term osteoarthritis prognosis is not improved by corticosteroid treatments. Here we investigate what could underlie this phenomenon by measuring the short term corticosteroid response of OA-Mf. Methods We determined the genome-wide transcriptomic response to corticosteroids of end-stage osteoarthritic joint synovial macrophages (OA-Mf). This was compared with LPS-tolerized
-
Low CD4 + T cell count is related to specific anti-nuclear antibodies, IFNα protein positivity and disease activity in systemic lupus erythematosus pregnancy Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-03-09 Agnes Torell, Marit Stockfelt, Kaj Blennow, Henrik Zetterberg, Tansim Akhter, Dag Leonard, Lars Rönnblom, Sofia Pihl, Muna Saleh, Christopher Sjöwall, Helena Strevens, Andreas Jönsen, Anders A. Bengtsson, Estelle Trysberg, Maria Majczuk Sennström, Agneta Zickert, Elisabet Svenungsson, Iva Gunnarsson, Johan Bylund, Bo Jacobsson, Anna Rudin, Anna-Carin Lundell
Lymphopenia, autoantibodies and activation of the type I interferon (IFN) system are common features in systemic lupus erythematosus (SLE). We speculate whether lymphocyte subset counts are affected by pregnancy and if they relate to autoantibody profiles and/or IFNα protein in SLE pregnancy. Repeated blood samples were collected during pregnancy from 80 women with SLE and 51 healthy controls (HC)
-
LATS2 degradation promoted fibrosis damage and rescued by vitamin K3 in lupus nephritis Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-03-09 Chen Cheng, Hao Yang, Chan Yang, Juan Xie, Jinshen Wang, Luping Cheng, Jianfu He, Honglian Li, Haoxing Yuan, Fangfang Guo, Minmin Li, Shuwen Liu
Lupus nephritis (LN) is the most common complication of systemic lupus erythematosus (SLE). The limited treatment options for LN increase the economic burdens on patients. Because fibrotic progression leads to irreversible renal damage in LN patients and further progresses to chronic kidney disease (CKD) and the end stage of renal disease (ESRD), developing new targets to prevent LN fibrotic progression
-
Effect of remission, clinical remission with active serology, and glucocorticoid dosage on the pregnancy outcome of pregnant patients with systemic lupus erythematosus Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-03-09 Takehiro Nakai, Nanase Honda, Eri Soga, Sho Fukui, Ayako Kitada, Naoto Yokogawa, Masato Okada
Remission is a key treatment target in systemic lupus erythematosus (SLE) management. Given the direct correlation between lupus flares and elevated risks of adverse pregnancy outcomes (APOs), securing remission before conception becomes crucial. However, the association between clinical remission with active serology, and the risk of APOs is not thoroughly understood. Additionally, determining the
-
Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis Rheumatology (IF 5.5) Pub Date : 2024-03-09 Dinesh Khanna, Frank Kramer, Josef Höfler, Mercedeh Ghadessi, Peter Sandner, Yannick Allanore, Christopher P Denton, Masataka Kuwana, Marco Matucci-Cerinic, Janet E Pope, Tatsuya Atsumi, Radim Bečvář, László Czirják, Ellen De Langhe, Eric Hachulla, Tomonori Ishii, Osamu Ishikawa, Sindhu R Johnson, Valeria Riccieri, Elena Schiopu, Richard M Silver, Vanessa Smith, Chiara Stagnaro, Virginia Steen, Wendy
Objective To examine disease and target engagement biomarkers in the RISE-SSc trial of riociguat in early diffuse cutaneous systemic sclerosis and their potential to predict the response to treatment. Methods Patients were randomized to riociguat (n = 60) or placebo (n = 61) for 52 weeks. Skin biopsies and plasma/serum samples were obtained at baseline and week 14. Plasma cyclic guanosine monophosphate
-
Characteristics associated with patient-reported treatment success in psoriatic arthritis Rheumatology (IF 5.5) Pub Date : 2024-03-09 Christeen Samuel, Amanda Finney, Thomas Grader-Beck, Uzma Haque, John Miller, Suzanne M Grieb, Laura Prichett, Ana-Maria Orbai
Objectives To determine characteristics associated with patient-reported treatment success in psoriatic arthritis (PsA). Methods Rheumatologist-diagnosed PsA patients fulfilling the CASPAR classification were recruited from a single center. PsA outcome measures included: 66/68 swollen/tender joint counts, Leeds/SPARCC dactylitis/enthesitis indices, psoriasis body surface area (BSA), and patient-reported
-
Anti-histone and anti-nucleosome rather than anti-dsDNA antibodies associate with IFN-induced biomarkers in Sudanese and Swedish Systemic Lupus Erythematosus patients Rheumatology (IF 5.5) Pub Date : 2024-03-09 Sahwa Elbagir, NasrEldeen A Mohammed, Vilija Oke, Anders Larsson, Jan Nilsson, Amir Elshafie, Elnour M Elagib, Musa A M Nur, Iva Gunnarsson, Elisabet Svenungsson, Johan Rönnelid
Objectives In SLE, anti-dsDNA can co-occur with autoantibodies against other chromatin components, like histones and nucleosomes. These antibodies induce type-1 interferon production, a hallmark of SLE. We measured antinuclear antibody (ANA) sub-specificities and investigated their associations to inflammatory biomarkers including interferon-regulated chemokines. Methods We included 93 Sudanese and
-
A patient centered assessment of the 2016 ACR-EULAR Myositis Response Criteria: evaluating the meaningfulness of response Rheumatology (IF 5.5) Pub Date : 2024-03-09 Didem Saygin, Anjana Chandrasekhara Pillai, Siamak Moghadam-Kia, Chester V Oddis, Dianxu Ren, Catherine Najem, Harman Dhatt, Rohit Aggarwal
Objectives The ACR-EULAR Myositis Response Criteria (Total Improvement Score [TIS]) is a composite measure calculated using changes in myositis core set measures. It is unclear if achieving improvement per TIS reflects improvement in any symptoms of myositis patients. In this study, we examined the association between achieving TIS improvement and patient-centered outcome measures (PCOMs). Methods
-
Rheumatoid arthritis and risk of osteoarticular infection and death following Staphylococcus aureus bacteraemia: A nationwide cohort study Rheumatology (IF 5.5) Pub Date : 2024-03-09 Sabine S Dieperink, Mette Nørgaard, Frank Mehnert, Louise B Oestergaard, Thomas Benfield, Christian Torp-Pedersen, Andreas Petersen, Bente Glintborg, Merete L Hetland
Objectives Osteoarticular infection (OAI) is a feared complication of Staphylococcus aureus bacteraemia (SAB) and is associated with poor outcomes. We aimed to explore risk of OAI and death following SAB in patients with and without rheumatoid arthritis (RA) and to identify risk factors for OAI in patients with RA. Methods Danish nationwide cohort study of all patients with microbiologically verified
-
APOE in fat pad and synovium contributes to knee OA Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-03-07 Robert Phillips
New research has identified apolipoprotein E expressed by fibroblasts and macrophages in the infrapatellar fat pad and synovium as a pathogenetic mediator and potential therapeutic target in knee osteoarthritis.
-
Immunogenic Xist ribonucleoproteins drive sex-biased autoimmunity Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-03-07 Jessica McHugh
Ribonucleoprotein complexes containing Xist, a long non-coding RNA involved in X chromosome inactivation, are immunogenic and promote autoimmune responses.
-
Identification of early risk factors for anti-citrullinated-protein-antibody positive rheumatoid arthritis—a prospective cohort study Rheumatology (IF 5.5) Pub Date : 2024-03-08 Alexandra Cîrciumaru, Yogan Kisten, Monika Hansson, Linda Mathsson-Alm, Vijay Joshua, Heidi Wähämaa, Malena Loberg Haarhaus, Joakim Lindqvist, Leonid Padyukov, Sergiu-Bogdan Catrina, Guozhong Fei, Nancy Vivar, Hamed Rezaei, Erik af Klint, Aleksandra Antovic, Bence Réthi, Anca I Catrina, Aase Hensvold
Objective Individuals positive for anti-cyclic-peptide-antibodies (anti-CCP) and musculoskeletal complaints (MSK-C) are at risk for developing rheumatoid arthritis (RA). In this study we aimed to investigate factors involved in arthritis progression. Methods Anti-CCP2-positive individuals with MSK-C referred to a rheumatologist were recruited. Individuals lacked arthritis at clinical and ultrasound
-
Eosinophils regulate bone remodelling Nat. Rev. Rheumatol. (IF 33.7) Pub Date : 2024-03-07 Sarah Onuora
Results of a new study indicate that eosinophils have a role in maintaining bone homeostasis through their inhibitory effects on bone-resorbing osteoclasts.
-
B cell receptor repertoire analysis in primary Sjogren’s syndrome salivary glands identifies repertoire features associated with clinical activity Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-03-07 Ling Chang, Zihan Zheng, Yiwen Zhou, Kun Liu, Yinong Li, Bing Zhong, Zihua Zhao, Chengshun Chen, Can Qian, Qingshan Ni, Qinghua Zou, Yuzhang Wu, Jingyi Li, Liyun Zou
Primary Sjogren’s syndrome (pSS) is a complex autoimmune disease featuring damage to salivary and lacrimal glands, with the possibility of manifestations across multiple organs. Antibody-producing B cells have long been appreciated to play a significant role in pSS pathogenesis, with a number of autoreactive antibody species having been identified to be elevated in pSS patients. While several studies
-
Cancer risk with tocilizumab/sarilumab, abatacept, and rituximab treatment in patients with rheumatoid arthritis: a Danish cohort study Rheumatology (IF 5.5) Pub Date : 2024-03-07 Rasmus Westermann, René Lindholm Cordtz, Kirsten Duch, Lene Mellemkjaer, Merete Lund Hetland, Bergur Magnussen, Lene Dreyer
Objectives To investigate cancer risk in rheumatoid arthritis (RA) patients treated with tocilizumab/sarilumab, abatacept, or rituximab compared with those who received tumour necrosis factor inhibitors (TNFi) and compared with biological disease-modifying anti-rheumatic drugs (bDMARD) naïve RA patients. Methods Nationwide registry-based cohort study of RA patients initiating treatment with tocilizumab/sarilumab
-
Osteoporosis is associated with anti-topoisomerase I positivity and glucocorticoids use in patients with systemic sclerosis Rheumatology (IF 5.5) Pub Date : 2024-03-06 Charles Midol, Edgar Wiebe, Elise Siegert, Dörte Huscher, Hélène Béhal, David Launay, Eric Hachulla, Eric L Matteson, Frank Buttgereit, Vincent Sobanski
Objectives Patients with systemic sclerosis (SSc) are at increased risk for osteoporosis (OP) and associated fragility fractures. This study aimed to identify underlying risk factors for these conditions in patients with SSc. Methods This cross-sectional study was based on a large prospective cohort of patients with SSc using retrospectively collected bone health data. OP was defined as the presence
-
Urinary prostanoids are elevated by anti-TNF and anti-IL6 receptor disease-modifying antirheumatic drugs but are not predictive of response to treatment in early rheumatoid arthritis Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-03-05 Jianyang Liu, Helena Idborg, Marina Korotkova, Kristina Lend, Ronald van Vollenhoven, Jon Lampa, Anna Rudin, Dan Nordström, Bjorn Gudbjornsson, Gerdur Gröndal, Till Uhlig, Kim Hørslev-Petersen, Merete Lund Hetland, Mikkel Østergaard, Michael Nurmohamed, Per-Johan Jakobsson
Disease-modifying antirheumatic drugs (DMARDs) are widely used for treating rheumatoid arthritis (RA). However, there are no established biomarkers to predict a patient’s response to these therapies. Prostanoids, encompassing prostaglandins, prostacyclins, and thromboxanes, are potent lipid mediators implicated in RA progression. Nevertheless, the influence of DMARDs on prostanoid biosynthesis in RA
-
Nasal Rim Sign: A clinical manifestation of dermatomyositis Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-03-05 Sweta Subhadarshani, Madeline Hunt, Kerith Spicknall
-
Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis on anti-interleukin-1 or -6 therapy Rheumatology (IF 5.5) Pub Date : 2024-03-05 Kadir Ulu, Emil Aliyev, Elif Kılıç Könte, Ayşe Tanatar, Şeyma Türkmen, Şeyda Doğantan, Zehra Kızıldağ, Belde Kasap Demir, Deniz Gezgin Yıldırım, Gülçin Otar Yener, Kübra Öztürk, Özge Baba, Ceyhun Açarı, Gülşah Kılbaş, Sema Nur Taşkın, Fatih Haşlak, Şengül Çağlayan, Esra Bağlan, Hatice Adıgüzel Dundar, Özge Başaran, Kenan Barut, Şerife Gül Karadağ, Taner Coşkuner, Hafize Emine Sönmez, Selçuk Yüksel
Objectives The aim of this study is to investigate the effect of anti-interleukin (IL)-1/-6 biologics on systemic juvenile idiopathic arthritis (sJIA)-associated macrophage activation syndrome (MAS). Methods Demographic, clinical, and laboratory data of patients followed up with a diagnosis of sJIA-associated MAS assessed from sixteen pediatric rheumatology centers across the country. The clinical
-
Vaccination and the risk of systemic lupus erythematosus: a meta-analysis of observational studies Arthritis Res. Ther. (IF 4.9) Pub Date : 2024-03-04 Meijiao Wang, Huanpeng Gu, Yingqi Zhai, Xuanlin Li, Lin Huang, Haichang Li, Zhijun Xie, Chengping Wen
This meta-analysis aims to explore the potential link between vaccines and systemic lupus erythematosus (SLE). We systematically searched PubMed, Cochrane Library, and Embase for observational studies from inception to September 3, 2023, using medical subject headings (MeSH) and keywords. Study quality was assessed using the NOS scale. Statistical analyses were conducted using STATA software (version
-
Genetic Approaches to Study Rheumatic Diseases and its Implications in Clinical Practice Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-03-04 Dorota Rowczenio, Ivona Aksentijevich
-
Phosphatidic acid promotes the generation of IL‐17A producing double‐negative T cell by enhancing mTORC1 signaling in lupus Arthritis Rheumatol. (IF 13.3) Pub Date : 2024-03-04 Wenjing Li, Xiaojun Tang, Yuanyuan Zheng, Xuefeng Xu, Nan Zhao, Betty P. Tsao, Xuebing Feng, Lingyun Sun
-
Inclusion-body myositis associated with Sjögren’s disease: clinical characteristics and comparison with other Sjögren-associated myositis Rheumatology (IF 5.5) Pub Date : 2024-03-02 Quentin Astouati, Thomas Machet, Camille Houssais, Jean-Baptiste Noury, Yves Allenbach, Laure Gallay, Baptiste Quere, Florence Assan, Olivier Benveniste, Jonathan Broner, Pierre Duffau, Alexandra Espitia, Anne Grasland, Gilles Hayem, Véronique Le Guern, Nihal Martis, Kuberaka Mariampillai, Gaëtane Nocturne, Xavier Mariette, Alain Meyer, Denis Mulleman, Valérie Devauchelle-Pensec, Aurore Collet, David
Objectives To describe the characteristics of patients with Sjögren’s disease (SjD) and inclusion-body myositis (IBM), and how they compare to SjD patients with other inflammatory myopathies (IM). Methods Patients were retrospectively recruited from 13 French centers and included if they met the ACR/EULAR criteria for SjD and for IM. They were categorized as SjD-IBM if sub-criteria for IBM were met
-
Diagnostic value of a novel salivary gland ultrasound scoring system in IgG4-related sialadenitis Rheumatology (IF 5.5) Pub Date : 2024-03-02 Mingzhu Zhou, Shanshan Zhang, Xiaoyan Xie, Wei Li, Li Cui, Hanxue Zhao, Sumei Tang, Xiangdong Hu, Shanshan Wu, Jiajing Peng, Huilian Huang, Wei Ren, Ying Zhang, Ning Xu, Pengfei Sun, Yiqun Liu, Zuyan Zhang, Guangyan Yu, Yanying Liu, Yin Su
Objectives To develop a novel ultrasound scoring system for the major salivary glands in patients with immunoglobulin G4-related sialadenitis (IgG4-RS) and assess its diagnostic value in a multicenter cohort of Chinese patients. Methods Twenty clinicians (rheumatologists, stomatologists, and radiologists) participated. The study was conducted in four steps: (1) defining the ultrasonography (US) elements
-
Flare in Systemic Lupus Erythematosus: Lost in Translation? J. Rheumatol. (IF 3.9) Pub Date : 2024-03-01 Eric F Morand, Sarah A Jones
The concept of systemic lupus erythematosus (SLE) as a relapsing and remitting condition is deeply embedded in how clinicians perceive this disease. This perception arises from observations of periods of low disease activity interspersed with episodes of more active disease, which are commonly referred to as "flares."
-
Analyzing Gender Disparities in Ankylosing Spondylitis: Exploring the Factors Behind Severe Sacroiliac Joint Disease Without Spinal Involvement. J. Rheumatol. (IF 3.9) Pub Date : 2024-03-01 Laura Berbel-Arcobé, Diego Benavent, Joan Miquel Nolla, Xavier Juanola
We have read with interest the paper by Ridley et al1 on the radiographic damage discordance between the sacroiliac joints (SIJs) and the spine in patients with ankylosing spondylitis (AS) from the Prospective Study of Outcomes in AS (PSOAS) cohort, which includes patients from the United States and Australia. Their results have encouraged us to investigate the prevalence of severe SIJ disease without
-
Putting Patients First. J. Rheumatol. (IF 3.9) Pub Date : 2024-03-01 Victor S Sloan
They were some of the hardest phone calls I'd ever had to make. After more than 25 years of practice, I had to tell patients I'd been seeing for that entire period that I could no longer be their doctor.
-
Perceived Access to Health Care of Indigenous Peoples in Canada with Rheumatoid Arthritis and their First-Degree Relatives. J. Rheumatol. (IF 3.9) Pub Date : 2024-03-01 Dana Wiens, Irene A Smolik, Dylan MacKay, Amanda Fowler-Woods, David B Robinson, Cheryl Barnabe, Hani S El-Gabalawy, Liam J O'Neil
There are complex and interrelated factors that lead to inequitable healthcare delivery in Canada. Many of the factors that underlie these inequities for Canada's geographically dispersed Indigenous Peoples remain underexamined.
-
Immune Checkpoint Inhibitor associated Remitting Seronegative Symmetrical Synovitis with Pitting Edema (ICI-RS3PE): Description of a New Entity by CanRIO. J. Rheumatol. (IF 3.9) Pub Date : 2024-03-01 Azin Rouhi, Shahin Jamal, Lourdes Gonzales Arreola, David Moon, Marie Hudson, Janet Roberts, Alexandra Ladouceur, Carrie Ye
Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) is characterized by symmetrical synovitis with pitting edema and negative rheumatoid factor (RF). It has been described in setting of malignancy, suggesting a paraneoplastic association. With the increasing use of immune checkpoint inhibitors (ICIs) for the treatment of cancers and emergence of immune related adverse event (irAEs)
-
Pneumocephalus and Cerebral Abscess in Granulomatosis With Polyangiitis. J. Rheumatol. (IF 3.9) Pub Date : 2024-03-01 Yasutaka Okita, Masashi Okamoto, Jun Fujimoto, Atsushi Kumanogoh
Granulomatosis with polyangiitis (GPA) is a systemic autoimmune disease that causes necrotizing vasculitis of small- to medium-sized blood vessels and necrotizing granulomatous inflammation, primarily of the upper and lower respiratory system. A 33-year-old woman presented with a 16-month history of headaches, nasal obstruction, and anosmia.
-
The Scleroderma Tango: Unraveling the Delicate Dance of Diastolic Dysfunction and Interstitial Lung Disease. J. Rheumatol. (IF 3.9) Pub Date : 2024-03-01 Vivek P Jani, Monica Mukherjee
In this issue of The Journal of Rheumatology, Fairley and colleagues investigated the effects of concomitant left ventricular diastolic dysfunction (LVDD) in a small cohort of patients with systemic sclerosis (SSc)-associated interstitial lung disease (ILD) derived from the larger Australian Scleroderma Cohort Study.1 Consistent with prior reports, the authors found that patients with SSc-ILD with
-
Orbital and Optic Nerve Sheath Involvement and Pupil-Involving Cranial Nerve 3 Palsy in Giant Cell Arteritis. J. Rheumatol. (IF 3.9) Pub Date : 2024-03-01 Salma A Dawoud, Noor-Us-Sabah Ahmad, Erin M Shriver, Sophia M Chung
Giant cell arteritis (GCA) can present with atypical presentations that are diagnostically challenging. An 84-year-old woman with a history of breast adenocarcinoma treated with lumpectomy and radiation 2 years prior presented with a seizure-like episode.